drugset / Trial / NCT00384800
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary objectives: 1. To determine the disease stabilization rate; 2. To assess the progression-free survival and overall survival; 3. To establish the safety profile; 4. To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.
Timeline
- Start
- 2006-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegafur/Uracil | Unknown | — | Oral |
| Subject | Thalidomide | Other / unclassified | — | Oral |